Laurence Albiges
@AlbigesL
Medical Oncologist - GU oncology; Chair Med Onc Dpmt @gustaveroussy ; Professor of medecine @UniversiteParisSaclay #kidneycancer #RCC views are mine
ID:906519958066221056
09-09-2017 14:09:35
273 Tweets
2,5K Followers
108 Following
Follow People
Still time to apply 👉 #ESMOPreceptorship on Metastatic #BladderCancer & #KidneyCancer : molecular pathology & diagnosis as contributing factors to heterogeneity, assessment & multidisciplinary tx, advances in tx & novel targets
🔗 ow.ly/FZeH50QBJBl
#blcsm #kcsm Laurence Albiges
Proud of Gustave Roussy GU group celebrating 20th anniversary #GU24 🎂
Thrilled to contribute to 20years of advances in GU cancers care !
Missing Pierre Blanchard, MD Alberto Bossi Christophe Massard
The #MCCRWorkshop enables peer #mentoring and #CareerDevelopment for early-career #oncology professionals. Apply now to gain access to mentors and develop protocols ready for submission.
⏲️ Deadline: 1 February 2024.
ow.ly/m7TG50QtYnF
EORTC AACR #CancerResearch
Listening to 'December 2023 – Eur Urol Oncology highlights' at buzzsprout.com/2220728/142769… European Urology Oncology European Association of Urology (EAU) Ashish M. Kamat, MD, MBBS Riccardo Campi Cathy Elena Castro Alicia Morgans, MD, MPH Ploussard Guillaume Jeremy Teoh Laurence Albiges Declan Murphy
JUST IN: U.S. FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors!
A great day for the field and a new option for our Kidney Cancer patients!!!!
Via ASCO #FDAAlerts OncoAlert
Study presented at ESMO - Eur. Oncology #ESMO3 by…
Starting shortly #ESMOIO23 full #GU session on hot topic in #IO all stars ⭐️ panel
Guillermo de Velasco
Bernard-Tessier Gustave Roussy
Tom Powles Uromigos
Pignot Géraldine Institut Paoli-Calmettes (IPC) GETUG Unicancer Association Française d'Urologie - AFU
Do not miss ESMO - Eur. Oncology !
#ESMOAsia23 GU educational on perioperative therapy chairs Deborah Mukherji Ravindran Kanesvaran
Excellent Enrique Grande making clear neoadj/adj landscape in UC!
Content available here tomorrow:
oncologypro.esmo.org/meeting-resour…
Fantastic discussion Deborah Mukherji #ESMOAsia23 highlighting
(1) higher de novo M+ disease in HSPC in Asia: 10% higher in recent ARASENS Chinese substudy
(2) lower rate of intensification therapy in mHSPC Advanced Prostate Cancer Consensus Conference Lisa Pickering 💉💙 Enrique Grande ESMO - Eur. Oncology Christopher Sweeney, MBBS Uromigos
#pragmatic #ESMOAsia23 Low dose IO including de-escalation strategy… pending prospective trials PULSE Benjamin Besse Gustave Roussy in NSCLC and MOIO Dr Gravis Institut Paoli-Calmettes (IPC) across tumor type GETUG Unicancer
Watch below for a message from Dr. David McDermott for Tonight's Symposium! Join the #RCC experts, Sumanta K. Pal, MD, FASCO, Laurence Albiges, and David F. McDermott, MD, for a live educational event tonight, Friday, November 10, at 6:45 pm CST during #IKCSNA23 ! bit.ly/Nashville23T #MedEd
Cancers du rein et des voies urinaires : nouvelles stratégies thérapeutiques présentées à l' #ESMO2023
Avec Laurence Albiges et Constance Thibault
Gustave Roussy Hôpital européen Georges-Pompidou AP-HP
ms.spr.ly/60149hIFE
The #ESMO23 Highlight videos series - daily interviews with selected LBA presenters.🔗ow.ly/xJ6250Q1rSA
With Laurence Albiges, Yelena Y. Janjigian MD, Ben Solomon, Herbert Loong, Michiel van der Heijden, Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ, Domenica Lorusso, Julien Hadoux, Filippo Pietrantonio, Funda Meric-Bernstam, Aaron…
#ESMO23 : Over 3,400 slides, webcasts, abstracts & ePosters are now available on OncologyPRO 👉 practice-changing data and state-of-the-art educational content from more than 20 tracks.
ow.ly/9sNL50Q5QFn
#MedTwitter #OncTwitter
Rule clarification.The photo with the most ‘likes’ by Friday wins. If you want to support someone else you can post a photo, and say in the text who you are supporting instead of yourself. We then add up the likes. Top 2 go into a vote run off if it’s close Shilpa Gupta Toni Choueiri, MD
Just out in JAMA Oncology NIVOREN Gustave Roussy ancillary study Félix Lefort Corticosteroids use impact in pts with mRCC under nivolumab: longer PFS&OS - 2 potential explanations (i)steroid mainly for IrAEs, selected stronger immune response (ii)persistent signif. immortal time bias